title: Effect of human chorionic gonadotrophin coadministration on ovarian steroidogenic and folliculogenic activities in cyclophosphamide treated albino rats.
abstract: Quantitative evaluation of ovarian Delta5,3beta- hydroxysteroid dehydrogenese (HSD) and 17beta - HSD activities along with radioimmunoassay of plasma levels of gonadotrophins (FSH and LH), and estradiol (E2), and quantification of different types of developing follicles and regressive follicles were noted in mature rats of the Wistar strain following treatment with cyclophosphamide at a dose of 5 mg/kg body weight/day for 28 days. A significant reduction in plasma levels of LH and E2 along with significant diminution in the activities of ovarian Delta5,3beta -HSD and 17beta- HSD were observed following cyclophosphamide treatment for 28 days without any change in the plasma level of FSH. This treatment also produced a marked degree of degeneration in different types of follicles. Coadministration of hCG at 5 IU/kg body weight/day for 28 days in the cyclophosphamide-treated group provided significant protection except with respect to plasma LH. These results suggest the possibility of an indirect action of cyclophosphamide at the level of the ovary.
authors: Reproductive Endocrinology and Family Welfare Unit, Department of Human Physiology with Community Health, Vidyasagar University, Midnapore -721 102, West Bengal, India.
authors: S
authors: S
authors: Ghosh
authors: M
authors: M
authors: Misro
authors: U B
authors: UB
authors: Das
authors: R
authors: R
authors: Maiti
authors: J M
authors: JM
authors: Debnath
authors: D
authors: D
authors: Ghosh
mesh_terms: D015067:17-Hydroxysteroid Dehydrogenases / Q000378:metabolism; D015096:3-Hydroxysteroid Dehydrogenases / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000494:pharmacology*; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology*; D004338:Drug Combinations; D004958:Estradiol / Q000097:blood; D004971:Estrus / Q000187:drug effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D009929:Organ Size / Q000187:drug effects; D006080:Ovarian Follicle / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D010053:Ovary / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar
chemical_list: D018906:Antineoplastic Agents, Alkylating; D006063:Chorionic Gonadotropin; D004338:Drug Combinations; D007166:Immunosuppressive Agents; D004958:Estradiol; D003520:Cyclophosphamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D015067:17-Hydroxysteroid Dehydrogenases; D015096:3-Hydroxysteroid Dehydrogenases; C031954:delta(5)-3 beta-hydroxysteroid dehydrogenase; C044256:3 (or 17)-beta-hydroxysteroid dehydrogenase